Skip to main content
Clinical Trials/DRKS00029024
DRKS00029024
Completed
Phase 2

Delving in the behavioural and neural correlates of pain perception using a therapy combining mindfulness meditation and transcranial direct current stimulation for the treatment of fibromyalgia syndrome. - Med_tDCS_Fibro

niversitätsmedizin Göttingen0 sites44 target enrollmentMay 31, 2022

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
M79.7
Sponsor
niversitätsmedizin Göttingen
Enrollment
44
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 31, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversitätsmedizin Göttingen

Eligibility Criteria

Inclusion Criteria

  • 1\. Stable disease for at least 6 months prior to participation
  • 2\. No new treatment approaches over the preceding 3 months
  • 3\.Stable allowed fibromyalgia related medications (see below) for \= 4 weeks prior to the
  • study. List of allowed medications:
  • \-Intake of NSAIDs and coxibs as required (bei Bedarf), but participants must not take it 24
  • hours prior to study visits.
  • \- Commonly used antidepressants for FMS will be allowed.
  • \-Low dose (\<25 mg THC content/day) of medical oromucosal cannabinoid therapy (e.g.
  • dronabinol, nabiximols, extracts). The participant has to refrain from taking it up to 24 hours
  • prior to study visits.

Exclusion Criteria

  • 1\. Treatment with any of the following medications:
  • \- Strong opioids, or taking more than three medications for fibromyalgia symptom relief.
  • \- Carbamazepine, benzodiazepines, phenytoin, gabapentin, pregabalin; calcium channel
  • antagonists (e.g. flunarizine), NMDA receptor antagonists (e.g. dextromethorphan, memantine),
  • anticholinergics.
  • \- Therapeutic local anesthetic infiltration of the spinal column within the last 4 weeks
  • before baseline and/or planned during the trial period.
  • \- Topically administered medication with influence on the study target during the study
  • Inhaled or smoked cannabinoids for medical use.
  • 2\. presence of any major, acute or unstable medical, neurological or psychiatric disorder,

Outcomes

Primary Outcomes

Not specified

Similar Trials